Table 1.
Baseline clinicopathologic characteristics between the low- and high-risk groups in the MMP cohort.
| Variables | MMP (n = 526) | ||
|---|---|---|---|
| Low (n = 335) | High (n = 191) | p-Value | |
| Age (mean ± SD) | 53.27 ± 9.07 | 52.62 ± 10.44 | 0.473 |
| Height (mean ± SD) | 159.23 ± 5.41 | 158.81 ± 5.06 | 0.380 |
| Weight (mean ± SD) | 60.54 ± 10.09 | 60.62 ± 8.09 | 0.920 |
| BMI (mean ± SD) | 23.87 ± 3.78 | 24.05 ± 3.10 | 0.590 |
| Menarche age (mean ± SD) | 14.41 ± 1.76 | 14.42 ± 1.57 | 0.933 |
| Menopausal status | 0.656 | ||
| Premenopausal | 176 (52.5%) | 96 (50.3%) | |
| Postmenopausal | 158 (47.2%) | 95 (49.7%) | |
| Unknown | 1 (0.3%) | 0 (0.0%) | |
| Preoperative E2 (mean ± SD) | 73.15 ± 98.06 | 77.01 ± 98.34 | 0.676 |
| Preoperative FSH (mean ± SD) | 40.93 ± 36.29 | 38.24 ± 34.68 | 0.422 |
| Tumor size (mean ± SD) | 1.62 ± 0.65 | 1.97 ± 0.82 | <0.001 |
| Multiple lesions | 0.213 | ||
| No | 251 (74.9%) | 153 (80.1%) | |
| Yes | 84 (25.1%) | 38 (19.9%) | |
| HG | <0.001 | ||
| 1 | 123 (36.7%) | 30 (15.7%) | |
| 2 | 197 (58.8%) | 101 (52.9%) | |
| 3 | 12 (3.6%) | 59 (30.9%) | |
| Unknown | 3 (0.9%) | 1 (0.5%) | |
| NG | <0.001 | ||
| 1 | 32 (9.6%) | 3 (1.6%) | |
| 2 | 274 (81.7%) | 134 (70.2%) | |
| 3 | 28 (8.4%) | 53 (27.7%) | |
| Unknown | 1 (0.3%) | 1 (0.5%) | |
| EIC | 0.131 | ||
| No | 218 (65.1%) | 138 (72.2%) | |
| Yes | 108 (32.2%) | 46 (24.1%) | |
| Unknown | 9 (2.7%) | 7 (3.7%) | |
| LVI | 0.192 | ||
| No | 285 (85.1%) | 153 (80.1%) | |
| Yes | 49 (14.6%) | 37 (19.4%) | |
| Unknown | 1 (0.3%) | 1 (0.5%) | |
| SLN (mean ± SD) | 2.55±1.60 | 2.80±2.50 | 0.172 |
| Lymph node metastasis | 0.352 | ||
| No | 182 (54.3%) | 93 (48.7%) | |
| Yes | 148 (44.2%) | 93 (48.7%) | |
| Unknown | 5 (1.5%) | 5 (2.6%) | |
| Perinodal extension | 0.545 | ||
| No | 288 (86.0%) | 169 (88.5%) | |
| Yes | 46 (13.7%) | 22 (11.5%) | |
| Unknown | 1 (0.3%) | 0 (0.0%) | |
| Estrogen receptor | 0.271 | ||
| Low (0~5) | 11 (3.3%) | 10 (5.2%) | |
| High (6~8) | 324 (96.7%) | 181 (94.8%) | |
| Progesterone receptor | 0.112 | ||
| Negative | 39 (11.6%) | 34 (17.8%) | |
| Positive | 296 (88.4%) | 157 (82.2%) | |
| HER2 receptor | 0.062 | ||
| 0 | 77 (23.0%) | 50 (26.2%) | |
| 1+ | 156 (46.6%) | 69 (36.1%) | |
| 2+ | 102 (30.4%) | 72 (37.7%) | |
| Ki-67 (mean ± SD) | 13.17 ± 11.73 | 27.96 ± 18.89 | <0.001 |
BMI, body mass index; E2, estradiol; FSH, follicle-stimulating hormone; HG, histologic grade; NG, nuclear grade; EIC, extensive intraductal component; LVI, lympho-vascular invasion; SLN, sentinel lymph node; HER2, human epidermal growth factor receptor 2.